Thursday, 15 October 2026European Markets

SALMONES CAMANCHAC And SIPEF Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - SALMONES CAMANCHAC (SACAM.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SALMONES CAMANCHAC (SACAM.OL) kr39.20 9.13% 15.89%
SIPEF (SIP.BR) €55.10 5.51% 9.39%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SALMONES CAMANCHAC (SACAM.OL)

9.13% Forward Dividend Yield and 15.89% Return On Equity

Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. The company was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. is a subsidiary of Compañía Pesquera Camanchaca S.A.

Earnings Per Share

As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr4.72.

PE Ratio

SALMONES CAMANCHAC has a trailing twelve months price to earnings ratio of 8.31. Meaning, the purchaser of the share is investing kr8.31 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.89%.

Sales Growth

SALMONES CAMANCHAC's sales growth is negative 89.4% for the ongoing quarter and negative 89.9% for the next.

Volume

Today's last reported volume for SALMONES CAMANCHAC is 100 which is 94.77% below its average volume of 1913.

Revenue Growth

Year-on-year quarterly revenue growth declined by 34.9%, now sitting on 371.78M for the twelve trailing months.

More news about SALMONES CAMANCHAC.

2. SIPEF (SIP.BR)

5.51% Forward Dividend Yield and 9.39% Return On Equity

Sipef NV operates as an agro-industrial company. It operates through Palm, Rubber, Tea, and Bananas and Plants segments. The company offers crude palm oil, palm kernels, and palm kernel oil; ribbed smoked sheets, and scraps and lumps; cut, tear, and curl tea; and bananas and plants from Ivory Coast. It has operations in Indonesia, Papua New Guinea, Ivory Coast, Singapore, Europe, and internationally. The company was incorporated in 1919 and is headquartered in Schoten, Belgium.

Earnings Per Share

As for profitability, SIPEF has a trailing twelve months EPS of €6.7.

PE Ratio

SIPEF has a trailing twelve months price to earnings ratio of 8.22. Meaning, the purchaser of the share is investing €8.22 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.39%.

More news about SIPEF.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com